Cosmo Pharmaceuticals (COPN) H1 2024 earnings summary

Executive summary

• Achieved record H1 2024 revenue of €136.2 million, up from €43.7 million year-over-year, primarily driven by a $100 million upfront payment from Medtronic for AI partnership expansion, with another $100 million expected by year-end.

• Maintained a debt-free position, increased dividends, and held €133.4 million in cash and short-term investments at period end.

• Winlevi remains the #1 prescribed branded topical acne product in the U.S., with global expansion ongoing and EMA review in progress.

• Advanced pipeline with progress in androgenetic alopecia, distal ulcerative colitis, solid tumors, and AI-augmented endoscopy, including FDA approval for ColonPro and Genius Operating System.

• Strategic partnerships with Medtronic and NVIDIA are driving expansion in AI-powered health tech, with direct-to-consumer campaigns increasing product awareness.

Financial highlights

• H1 2024 revenue reached €136.2 million, up from €43.7 million in H1 2023, mainly from the Medtronic AI deal and strong product sales.

• Operating profit was €87.0 million (H1 2023: €7.1 million); net cash inflow from operations was €99.2 million.

• Cash position at June 30, 2024 was €133.4 million, with no debt.

• Dividend of €2 per share paid in July 2024.

• Gross margin improved to €113.1 million (H1 2023: €24.8 million); EPS was €4.72 (H1 2023: €0.09).

Outlook and guidance

• Full-year 2024 revenue guidance reaffirmed at €260 million–€270 million; operating profit guidance at €159 million–€169 million.

• Additional $100 million payment from Medtronic expected by year-end, contingent on new services and product delivery.

• EMA approval for Winlevi anticipated by end of 2024, with further global expansion planned.

• Key priorities include advancing R&D for GI Genius, globalizing Winlevi, and progressing clinical trials in pipeline assets.